Latest Lexeo Therapeutics News & Updates

See the latest news and media coverage for Lexeo. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Lexeo Therapeutics (Lexeo)

Clinical-stage genetic medicine company focused on cardiovascular and neurological diseases

lexeotx.com
Headquarters
New York, United States
Founded year
2018
Company type
Private company
Number of employees
100–200

Last updated

Latest news about Lexeo Therapeutics (Lexeo)

In short: Lexeo reported positive interim LX2020 data, including an 80% reduction in arrhythmia burden.

Company announcements

Lexeo

Lexeo Therapeutics reports second quarter 2026 financial results

Net loss was $25.9 million, cash of $234.2 million funds operations into 2028, and LX2020 received FDA RMAT designation.

Unlock all announcements with a

Media coverage

Seeking Alpha

Lexeo climbs after regulatory update on Friedreich ataxia drug

Lexeo Therapeutics (LXEO) stock rises as the FDA supports a potential accelerated approval pathway for LX2006, its treatment for Friedreich ataxia. Read more here.

Unlock all articles with a

Never miss news about Lexeo

Track Lexeo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.